Holia Hatoum-Makdad

Holia Hatoum-Makdad is a prominent inventor based in Hamden, CT (US). He has made significant contributions to the field of medical research, particularly in the area of angiogenesis inhibition. With a total of 4 patents to his name, he has established himself as a key figure in the development of innovative treatments for diseases related to abnormal angiogenesis.

Latest Patents

Among his latest patents, Holia has developed methods involving aryl ureas with angiogenesis inhibiting activity. This invention focuses on utilizing aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway, which is characterized by abnormal angiogenesis or hyperpermeability processes. His work in this area has the potential to lead to groundbreaking therapies for various medical conditions.

Career Highlights

Holia Hatoum-Makdad is currently associated with Bayer Healthcare LLC, where he continues to advance his research and innovations. His expertise in the field has allowed him to contribute significantly to the development of new therapeutic strategies aimed at combating diseases linked to angiogenesis.

Collaborations

Throughout his career, Holia has collaborated with notable professionals in the industry, including Jacques P Dumas and William Johnston Scott. These collaborations have further enriched his research and have played a vital role in the success of his inventions.

Conclusion

Holia Hatoum-Makdad is a distinguished inventor whose work in angiogenesis inhibition is paving the way for innovative medical treatments. His contributions to the field are invaluable, and his ongoing research promises to make a significant impact on healthcare.

Profile summary based on public USPTO records.